Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (10)
2024
-
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Clinical Genitourinary Cancer, Vol. 22, Núm. 5
-
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
ESMO Open, Vol. 9, Núm. 9
2021
-
Type 2 immunity is maintained during cancer-associated adipose tissue wasting
Immunotherapy Advances, Vol. 1, Núm. 1
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2018
-
Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes
Clinical Cancer Research, Vol. 24, Núm. 24, pp. 6115-6124
2017
-
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 389, Núm. 10064, pp. 67-76
2016
2015
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Journal of Translational Medicine, Vol. 13, Núm. 1
2014
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine